JPMORGAN CHASE & CO - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 64 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$46,000
+100.0%
21,811
+168.4%
0.00%
Q1 2021$23,000
+21.1%
8,126
-9.3%
0.00%
Q4 2020$19,000
-77.1%
8,959
-33.8%
0.00%
Q3 2020$83,000
+112.8%
13,539
+123.1%
0.00%
Q2 2020$39,000
-25.0%
6,068
-51.3%
0.00%
Q1 2020$52,000
-83.2%
12,463
-76.3%
0.00%
Q4 2019$310,000
+79.2%
52,490
+63.5%
0.00%
Q3 2019$173,000
-49.0%
32,111
-26.0%
0.00%
Q2 2019$339,000
+313.4%
43,406
+321.4%
0.00%
Q1 2019$82,00010,3000.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Eversept Partners, LP 522,042$1,117,1700.13%
XTX MARKETS LLC 26,041$56,0000.12%
Samsara BioCapital, LLC 300,000$642,0000.06%
Ikarian Capital, LLC 650,000$1,392,0000.06%
Opaleye Management Inc. 187,750$402,0000.05%
SABBY MANAGEMENT, LLC 108,026$231,0000.04%
Anson Funds Management LP 97,601$209,0000.04%
Virtu Financial LLC 83,221$178,0000.02%
GSA CAPITAL PARTNERS LLP 47,084$101,0000.02%
WEXFORD CAPITAL LP 19,512$42,0000.01%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders